[Cooperative study of surgical adjuvant chemotherapy for colorectal cancer (third report): five-year results. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan].
A randomized controlled study was carried out by the envelope method with 491 institutions in participation across the country in order to find an optimal surgical adjuvant chemotherapy for curatively resected colorectal cancer. The schedules for drug administration were different in four districts: ACNU + Futraful (FT) group and FT alone group in the Hokkaido-Shikoku district; the same schedule groups plus untreated group in the Chubu-Kinki district; MMC+FT group, FT alone group in the Tohoku-Kanto district; and ADM+FT group and FT alone group in the Chugoku-Kyushu district. The numbers of patients admitted to this study were 2,450 cases with colon cancer and 2,456 cases met the evaluation criteria of this study. The 5-year survival rate on the whole did not differ from combination therapy to single drug therapy in either colon cancer or rectal cancer, but in Dukes C rectal cancer the five-year survival rate tended to be higher with the combination therapies. In n2 (+) or a2(s) rectal cancer in particular, combination therapies with MMC and FT and with ADM and FT achieved significantly higher five-year survival rate, and the rate of local recurrence was significantly lower with ADM+FT.
Matsuda
T
T
1st Dept. of Surgery, Kinki University School of Medicine, Sayama, Japan.
Yasutomi
M
M
Kikuchi
K
K
Kasai
Y
Y
Abe
O
O
Kondo
T
T
Taguchi
T
T
Hattori
T
T
Inokuchi
K
K
Komi
N
N
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D015376:Nimustine / Q000008:administration & dosage; D011182:Postoperative Care; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage
D008937:Mitomycins; D015376:Nimustine; D005641:Tegafur; D016685:Mitomycin; D004317:Doxorubicin